GPBAR1 and steatosis: FXR and TGR5 activation can also improve metabolic health by reducing steatosis (fatty liver) via inhibiting lipogenesis and decreasing hepatic inflammation [52], as well as by mitigating high-fat diet (HFD)-induced glucose intolerance and insulin resistance [53].